(Q43279508)

English

Absence of QTc prolongation in a thorough QT study with subcutaneous liraglutide, a once-daily human GLP-1 analog for treatment of type 2 diabetes.

scientific article published on 8 September 2009

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19737980%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Absence of QTc prolongation in a thorough QT study with subcutaneous liraglutide, a once-daily human GLP-1 analog for treatment of type 2 diabetes (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19737980%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

type 2 diabetes

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Naum Khutoryansky

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19737980%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

author name string

Dhruba J Chatterjee

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19737980%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Milan Zdravkovic

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19737980%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Craig R Sprenger

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19737980%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Jeffrey S Litwin

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19737980%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

publication date

8 September 2009

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19737980%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

The Journal of Clinical Pharmacology

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19737980%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

49

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19737980%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19737980%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

1353-1362

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19737980%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Liraglutide: a once-daily GLP-1 analogue for the treatment of type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1177%2F0091270009339189

21 January 2018

Incretins and their role in the management of diabetes

1 reference

https://api.crossref.org/works/10.1177%2F0091270009339189

21 January 2018

Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide.

1 reference

https://api.crossref.org/works/10.1177%2F0091270009339189

21 January 2018

Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects

1 reference

https://api.crossref.org/works/10.1177%2F0091270009339189

21 January 2018

The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men.

1 reference

https://api.crossref.org/works/10.1177%2F0091270009339189

21 January 2018

One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1177%2F0091270009339189

21 January 2018

An open-label, parallel group study investigating the effects of age and gender on the pharmacokinetics of the once-daily glucagon-like peptide-1 analogue liraglutide.

1 reference

https://api.crossref.org/works/10.1177%2F0091270009339189

21 January 2018

The effect of moxifloxacin on QTc and implications for the design of thorough QT studies

1 reference

https://api.crossref.org/works/10.1177%2F0091270009339189

21 January 2018

Clinical evaluation of QT/QTc prolongation and proarrhythmic potential for nonantiarrhythmic drugs: the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use E14 guideline.

1 reference

https://api.crossref.org/works/10.1177%2F0091270009339189

21 January 2018

Ritonavir 100 mg does not cause QTc prolongation in healthy subjects: a possible role as CYP3A inhibitor in thorough QTc studies

1 reference

https://api.crossref.org/works/10.1177%2F0091270009339189

21 January 2018

Patient-reported rating of gastrointestinal adverse effects during treatment of type 2 diabetes with the once-daily human GLP-1 analogue, liraglutide

1 reference

https://api.crossref.org/works/10.1177%2F0091270009339189

21 January 2018

Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1177%2F0091270009339189

21 January 2018

Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial

1 reference

https://api.crossref.org/works/10.1177%2F0091270009339189

21 January 2018

Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study

1 reference

https://api.crossref.org/works/10.1177%2F0091270009339189

21 January 2018

Cardiac safety profile of nebulized formoterol in adults with COPD: a 12-week, multicenter, randomized, double- blind, double-dummy, placebo- and active-controlled trial

1 reference

https://api.crossref.org/works/10.1177%2F0091270009339189

21 January 2018

Etravirine has no effect on QT and corrected QT interval in HIV-negative volunteers

1 reference

https://api.crossref.org/works/10.1177%2F0091270009339189

21 January 2018

A definitive or thorough phase 1 QT ECG trial as a requirement for drug safety assessment

1 reference

https://api.crossref.org/works/10.1177%2F0091270009339189

21 January 2018

Identifiers

10.1177/0091270009339189

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19737980%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

release_lrkqm53xhrc3vjzsaebqlq7sky

1 reference

https://api.fatcat.wiki/v0/release/lrkqm53xhrc3vjzsaebqlq7sky

24 November 2022

based on heuristic

mapped directly with Wikidata item

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19737980%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43279508&oldid=1837796627"